LOSARTAN MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Losartan Market Size and Forecast – 2025 to 2032

 The Global Losartan Market is estimated to be valued at USD 1.68 Bn in 2025 and is expected to reach USD 2.23 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.1% from 2025 to 2032. The market growth is primarily driven by the increasing prevalence of hypertension and cardiovascular diseases worldwide, and growing awareness about the importance of managing high blood pressure.

Key Takeaways of the Global Losartan Market

• Hypertension is the leading segment in the market, contributing an estimated 50.2% of the share in 2025
• The 50 mg dosage of Losartan is expected to hold a notable 30.25% share in 2025, as it is commonly prescribed for patients with moderate hypertension or those needing more intensive blood pressure management.
• With regards to product type, the branded segment leads the market with an estimated 55.3% share in 2025.
• North America is expected to lead the market, holding a share of 38.3% in 2025.
• Asia Pacific is anticipated to be the fastest-growing region, with a market share of 25.2% in 2025.

Market Overview

The trend in the Losartan market is shifting towards the development of novel formulations and combination therapies to improve patient compliance and treatment outcomes. Additionally, there is a growing focus on expanding the market presence in emerging economies, where the demand for cost-effective and accessible antihypertensive medications is high. Furthermore, the expiration of patents for Losartan has opened up opportunities for generic manufacturers, leading to increased competition and affordability in the market.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Request sample copy

Losartan Market insights, By Indication - The hypertension segment is dominant due to the increasing global prevalence of hypertension and Losartan’s proven efficacy in effectively controlling blood pressure

In terms of by indication, hypertension segment is expected to contribute the highest share of the market with 50.2% in 2025, owing to several key factors. Firstly, the increasing prevalence of hypertension worldwide is a major driver for the demand for Losartan. Losartan, being a well-established and proven medication for managing hypertension, has gained widespread acceptance among healthcare providers and patients alike.

Moreover, Losartan's efficacy in reducing blood pressure and its favorable safety profile have further contributed to its dominant market share in the hypertension segment. Clinical studies have consistently demonstrated Losartan's ability to effectively lower systolic and diastolic blood pressure, making it a reliable choice for hypertension management.

For instance, in September 2023, the World Health Organisation’s (WHO) first report on hypertension revealed that approx. 1.3 billion people are affected globally, with 80% not receiving proper treatment. The condition leads to severe health issues like stroke and heart attack. Lifestyle changes and affordable medications can control hypertension, yet only 1 in 5 individuals manage it effectively. The WHO calls for increased focus on prevention and treatment, highlighting the significant economic benefits of improved management, which could prevent approx. 76 million deaths by 2050.

Losartan Market insights, By Strength - The 50 mg dosage holds the largest share as it serves as an ideal starting point for patients, offering a balance between efficacy and minimizing the risk of side effects

The 50 mg dosage of Losartan also holds a significant share of the market with an estimated 30.25% in 2025, as it is commonly used for patients with moderate hypertension or those who require more intensive blood pressure control. This strength provides a higher dose than the 12.5 mg and is frequently prescribed after an initial response is observed with lower doses.

The 50 mg strength ensures effective and sustained blood pressure management in patients who require stronger intervention, making it a common choice for healthcare providers. It strikes a balance between efficacy and safety, with patients able to tolerate this dose while achieving the desired therapeutic outcomes. As a result, the 50 mg strength is widely used in ongoing hypertension treatment and contributes to a substantial portion of the market.

Losartan Market Insights By Product Type - Branded Losartan dominates the market due to its strong reputation for quality, safety, and consistency, alongside significant marketing efforts, making it the preferred choice over generic alternatives

In terms of product type, the branded segment is expected to contribute the highest share of the market with 55.3% in 2025. Several factors have propelled the growth of branded Losartan products in the market. Firstly, branded Losartan has established a strong reputation for quality and reliability among healthcare providers and patients. Branded products undergo rigorous manufacturing processes and quality control measures, ensuring consistent efficacy and safety. This trust in the brand name has led to a preference for branded Losartan over generic alternatives, driving its market dominance. Moreover, branded Losartan products benefit from extensive marketing and promotional efforts by pharmaceutical companies.

Pricing Analysis of Losartan

• The pricing of Losartan in the U.S. is influenced by several key factors, including its generic status, pharmacy choice, insurance coverage, an\d dosage strength. Generic Losartan is widely available and significantly less expensive than its brand-name counterpart, Cozaar. For example, a typical retail price for 30 tablets of 50 mg generic Losartan is around USD 13, while the same quantity of brand-name Cozaar can cost over USD 150, highlighting the substantial price difference between generic and branded versions. Prices may vary depending on the pharmacy and whether a patient uses insurance or pays out-of-pocket, with some discount programs and coupons offering even lower prices, sometimes as little as USD 2 per prescription at select retailers.
• The average out-of-pocket cost for Losartan for insured patients in recent years has been reported at about USD 6.32 per prescription, reflecting copays rather than the full retail price. For uninsured patients, prices can be higher, but the widespread availability of generic Losartan helps keep costs manageable. Additionally, combination products like Losartan with hydrochlorothiazide are also competitively priced, with a 30-tablet supply often available for around USD 14. Overall, the affordability and accessibility of generic Losartan have made it a popular choice for hypertension management in the U.S., while the high cost of brand-name Cozaar limits its use mainly to those with specific insurance coverage or clinical need.

Regional Insights

To learn more about this report, Request sample copy

North America Losartan Market Analysis and Trends

In North America, the dominance in the global Losartan market can be attributed to several factors, with an estimated share of 38.3% in 2025. The region boasts a well-established healthcare infrastructure, with advanced medical facilities and a strong emphasis on research and development. The presence of major pharmaceutical companies, such as Merck & Co., Inc. and Novartis AG, further contributes to the market's growth. These companies have made significant investments in the development and commercialization of Losartan and other antihypertensive drugs. The favorable reimbursement policies and government initiatives to improve healthcare access have also played a crucial role in the market's dominance.

For instance, in February 2023, a recent Phase II clinical trial at Massachusetts General Hospital explored a promising treatment for locally advanced pancreatic cancer, combining the blood pressure drug Losartan with chemotherapy (FFX) and chemoradiation (CRT). The combination therapy showed potential in reducing tumor invasion and inhibiting immunosuppression, making it more effective in combating cancer before surgery. Losartan was found to improve immune response and blood vessel health, while tumor tissue from treated patients had more immune cells capable of killing cancer cells. These findings suggested that Losartan might have enhanced the effectiveness of chemotherapy and helped overcome resistance to cancer immunotherapy. Ongoing clinical trials were expected to further assess its impact on long-term survival.

Asia Pacific Losartan Market Analysis and Trends

Meanwhile, the Asia Pacific region is expected to exhibit the fastest growth in the global Losartan market with a share of 25.2% in 2025. The region's rapid economic development, coupled with improving healthcare infrastructure and rising disposable incomes, has fueled the demand for antihypertensive medications like Losartan. The increasing prevalence of hypertension, driven by factors such as sedentary lifestyles, unhealthy diets, and an aging population, has further propelled market growth.

Countries like China and India, with their large patient pools and expanding middle class, present significant opportunities for market players. The region has also witnessed the emergence of local pharmaceutical companies, such as Cipla, a leading Indian pharmaceutical company that has successfully launched multiple generic formulations of LosartanFor example, Cipla's Losartan Potassium tablets, marketed under the brand name Losartan, are widely used for treating hypertension and cardiovascular conditions, contributing significantly to the generic market segment.

Global Losartan Market Outlook for Key Countries

United States Losartan Market Trends

The U.S. market for Losartan is characterized by a strong presence of key players, robust healthcare infrastructure, and high awareness about hypertension management. Major companies, such as Merck & Co., Inc. and Novartis AG, have a significant market share and continue to invest in research and development. The country's large patient population, coupled with favorable reimbursement policies and a focus on preventive care, drives the demand for Losartan. The market also benefits from the presence of a well-established regulatory framework and stringent quality control measures.

According to the data provided by the Centers for Disease Control and Prevention in January 2025, high blood pressure is a major health issue in the U.S., affecting nearly half of all adults, about 120 million people. It significantly increases the risk of heart disease and stroke, which are leading causes of death, and was involved in nearly 686,000 deaths in 2022. Only about a quarter of affected adults have their blood pressure under control, and the condition costs the U.S. around USD 131 billion annually. Many people who need medication may not be taking it, highlighting ongoing challenges in managing hypertension nationwide.

China Losartan Market Trends

China's market for Losartan is experiencing rapid growth, driven by factors such as a large population, increasing prevalence of hypertension, and improving healthcare access. The government's initiatives to reform the healthcare system and expand insurance coverage have positively impacted the market. Local pharmaceutical companies, such as iangsu Hengrui is one of China's largest and most prominent pharmaceutical companies. It is actively involved in the production of generic and branded Losartan formulations. The company has invested heavily in research and development and has a strong presence in the domestic and international markets. The market also benefits from the country's growing middle class and increasing healthcare expenditure.

Germany Losartan Market Trends

Germany continues to lead the European market for Losartan, owing to its strong healthcare system, advanced medical research, and a focus on innovative therapies. The increasing prevalence of cardiovascular diseases is driving  the demand for antihypertensive medications like Losartan. Major players, such as Bayer AG and Boehringer Ingelheim GmbH, have a significant presence in the market and actively engage in research and development activities. The market also benefits from favorable government policies and a well-established regulatory framework.

For instance, according to the WifOR report, an independent economic research institute, Cardiovascular diseases (CVDs) are highly prevalent in Germany and are the leading cause of mortality. A significant portion of these diseases, particularly atherosclerotic cardiovascular disease (ASCVD), is preventable. However, up-to-date data quantifying the health and socioeconomic burden of ASCVDs in Germany are lacking.

Japan Losartan Market Trends

Japan's market for Losartan is characterized by a high prevalence of hypertension, an aging population, and a strong emphasis on preventive care. The country's universal healthcare system and favorable reimbursement policies support market growth. Major domestic players, such as Daiichi Sankyo Company, Limited, have a significant market share and focus on developing novel formulations and combination therapies. The market also benefits from the country's advanced medical research and collaborations between industry and academia.

For example, Daiichi Sankyo is one of Japan's leading pharmaceutical companies, with a strong presence in the hypertension treatment market. They have invested in developing new formulations and combination therapies, such as Losartan-based combinations, to improve patient adherence and treatment outcomes.

Brazil Losartan Market Trends

Brazil's market for Losartan is driven by factors such as a large population, increasing prevalence of hypertension, and government efforts to improve healthcare access. The market also benefits from the country's growing middle class and increasing healthcare awareness.

For example, EMS is one of Brazil's largest pharmaceutical companies and a key player in the production of generic drugs, including Losartan. The company focuses on providing affordable, high-quality generics to the Brazilian market, helping improve access to hypertension treatments.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments

• In May 2025, Scienture Holdings announced that Arbli (Losartan potassium oral suspension) has been listed in the FDA Orange Book with two patents, expiring in October 2041. These patents cover stable liquid formulations and treatment methods for Arbli, the first Food and Drug Administration (FDA)-approved ready-to-use oral liquid Losartan in the U.S. Arbli is approved for treating hypertension in patients over 6, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and managing diabetic nephropathy in type 2 diabetes patients.
• In March 2025, Scienture Holdings, Inc., a pharmaceutical company focused on innovative products, announced the U.S. FDA approval of SCN-102 (Arbli), a 10mg/mL oral suspension of Losartan potassium. Arbli is the first liquid formulation of Losartan approved for treating hypertension, reducing stroke risk, and managing diabetic nephropathy in certain type 2 diabetes patients. The oral suspension offers a convenient, ready-to-use option for patients aged 6 and older, eliminating compounding needs and providing a long shelf life. Hypertension, a key risk factor for stroke and heart disease, affects nearly half of U.S. adults.
• In September 2023, Granules India Limited announced that the US FDA has approved its ANDA for Losartan Potassium and Hydrochlorothiazide Tablets (50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg). The tablets are bioequivalent to Hyzaar Tablets by Organon LLC and are indicated for treating hypertension and reducing stroke risk in patients with hypertension and left ventricular hypertrophy. With this approval, Granules India now has a total of 60 ANDA approvals from the U.S. FDA. The current annual U.S. market for these tablets is approximately USD 73 million.

Top Strategies Followed by Global Losartan Market Players

• Established players in the global Losartan market are focusing on extensive research and development to innovate high-performance products. These companies are investing heavily in R&D to develop new formulations, delivery methods, and technologies that enhance the efficacy and safety of Losartan. By continuously innovating, they aim to maintain their competitive edge and meet the evolving needs of patients and healthcare providers.
• Mid-level players in the global Losartan market are adopting strategies focused on delivering cost-effective solutions to target price-sensitive consumers. These companies are optimizing their manufacturing processes and sourcing strategies to reduce production costs while maintaining product quality. By offering budget-friendly alternatives, they aim to capture a significant share of the market, particularly in regions with high demand for affordable medications.
• Small-scale players in the global Losartan market are targeting niche markets with unique features or innovative products. These companies are focusing on developing differentiated offerings that address specific patient needs or preferences. By specializing in niche segments, they aim to establish a loyal customer base and gain a competitive advantage in their targeted markets.

Market Report Scope

Losartan Market Report Coverage

Losartan Market Dynamics

To learn more about this report, Request sample copy

Losartan Market Driver - Increasing Prevalence of Hypertension

The global Losartan market is experiencing significant growth, primarily driven by the increasing prevalence of hypertension worldwide. Hypertension, or high blood pressure, is a chronic medical condition that affects millions of people globally. Losartan, an angiotensin II receptor antagonist, is widely prescribed for the treatment of hypertension due to its effectiveness in lowering blood pressure and reducing the risk of cardiovascular complications. As the number of individuals diagnosed with hypertension continues to rise, the demand for Losartan is expected to grow correspondingly. Factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population contribute to the increasing prevalence of hypertension. Moreover, the growing awareness about the importance of managing hypertension and the availability of generic Losartan products are further driving the market growth. As healthcare providers and patients alike recognize the benefits of Losartan in managing hypertension effectively, the market is poised for sustained expansion in the coming years.

For instance, in March 2023, according to WHO, Hypertension, affecting 1.28 billion adults globally. Most people with hypertension are unaware of their condition, and less than half receive proper treatment. It is a leading cause of premature death, with a target to reduce its prevalence by 33% by 2030. Risk factors include aging, obesity, lack of physical activity, high-salt diet, and excessive alcohol consumption. Lifestyle changes, such as improved diet and exercise, are key, though medication may still be necessary for some individuals. Regular blood pressure checks are crucial for diagnosis, typically when readings reach 140/90 mmHg or higher.

Losartan Market Opportunity - Increasing Demand for Personalized Medicine

The increasing demand for personalized medicine presents a significant opportunity for the Global Losartan Market. As healthcare shifts towards a more patient-centric approach, there is a growing need for targeted therapies that can be tailored to individual patient characteristics, such as genetic profile, comorbidities, and risk factors. By leveraging advances in pharmacogenomics and biomarker research, manufacturers can develop companion diagnostics and biomarker-based strategies to identify patient subgroups that are most likely to benefit from Losartan therapy.

For example, Novartis has a strong focus on precision medicine, leveraging genomic data to personalize therapies. Novartis can apply similar principles to Losartan as part of its cardiovascular portfolio, using biomarker-based strategies to identify the most suitable candidates for Losartan treatment and improve patient care.

This approach can optimize treatment outcomes, reduce adverse events, and improve patient adherence. Furthermore, the integration of real-world evidence and patient-reported outcomes can help to demonstrate the value of Losartan in the context of personalized medicine, supporting its inclusion in clinical guidelines and reimbursement policies.

Analyst Opinion (Expert Opinion)

• The global Losartan market is poised for steady growth driven by increasing hypertension prevalence, aging populations, and greater emphasis on preventive healthcare. Technological advancements in drug formulation, coupled with robust regulatory support for generic drugs, are further driving market expansion. Losartan, a widely prescribed angiotensin receptor blocker (ARB), continues to experience high demand due to its effectiveness in managing hypertension and its role in preventing stroke and kidney damage. The expansion of healthcare access in emerging markets and rising health awareness offer significant opportunities. However, the market faces challenges such as price competition from generics and the growing focus on newer, more effective alternatives for cardiovascular conditions.
• Notable events, such as the American College of Cardiology Annual Scientific Session and EuroPCR in the past few years, have fostered knowledge-sharing and showcased new technological advancements in hypertension treatment, strengthening collaboration between researchers, regulators, and healthcare providers. Real-world examples include Granules India’s recent ANDA approval for Losartan and hydrochlorothiazide tablets, enhancing global accessibility. Furthermore, government health initiatives promoting cardiovascular disease prevention, especially in developing regions, are expected to positively influence the market dynamics moving forward.

Market Segmentation

•  Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Hypertension
  • Left Ventricular Hypertrophy (LVH)
  • Diabetic Nephropathy
  • Others (Stroke, etc.)
•  Strength Insights (Revenue, USD Bn, 2020 - 2032)
  • 5 mg
  • 25 mg
  • 50 mg
  • 100 mg
•  Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Branded
  • Generic
•  Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric
  • Adult
  • Geriatric
•  Gender Insights (Revenue, USD Bn, 2020 - 2032)
  • Male
  • Female
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
•  Form Insights (Revenue, USD Bn, 2020 - 2032)
  • Tablet
  • Powder
  • Suspension
•  Source Insights (Revenue, USD Bn, 2020 - 2032)
  • Contract Manufacturing Organizations
  • In-House Manufacturing
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U,S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Organon LLC
  • Alembic Pharmaceuticals Ltd
  • Macleods Pharmaceuticals Ltd
  • Teva Pharmaceuticals USA
  • Aurobindo Pharma
  • Lupin Limited
  • Reddy’s Laboratories
  • Sun Pharmaceutical Industries Ltd
  • Zydus Cadila
  • Torrent Pharmaceuticals Ltd
  • Cipla Ltd
  • Glenmark Pharmaceuticals
  • Alkem Laboratories
  • Granules India Ltd
  • Micro Labs Ltd

Sources

Primary Research interviews

• Cardiologists and Hypertension Specialists
• Pharmacists and Pharmacy Managers
• Healthcare Providers in Cardiovascular Clinics
• Regulatory Experts in Pharmaceutical Development

Databases

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• World Health Organization (WHO)
• Centers for Disease Control and Prevention (CDC)
• National institutes of Health (NIH)
• National Heart, Lung, and Blood institute (NHLBI)

Magazines

• Pharmaceutical Technology
• Drug Development & Delivery
• The Lancet
• Cardiovascular Drugs and Therapy
• Journal of Hypertension
• Pharmaceutical Journal

Journals

• American Journal of Hypertension
• Journal of the American College of Cardiology
• European Heart Journal
• Hypertension
• Circulation Research 

Newspapers

• The New York Times
• The Washington Post
• The Guardian
• Financial Times
• Wall Street Journal

Associations

• American Heart Association (AHA)
• European Society of Cardiology (ESC)
• American College of Cardiology (ACC)
• international Society of Hypertension (ISH)
• Pharmaceutical Research and Manufacturers of America (PhRMA)

Public Domain Sources:

• U.S. National Library of Medicine (PubMed)
• National institutes of Health (NIH) Clinical Trials Database
• U.S. National institute on Aging (NIA)

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of information for Last 8 Years